This Program Project is made up of five functional components: Phase I Trials, Clinical Pharmacology, Phase II Solid Tumor, Phase II Hematology/Lymphoma, and Biostatistics, and an Administrative Core. The ultimate objective of the studies proposed in this Program Project is to improve the treatment, with the view to increasing the percentage of complete remissions and eventual cures, of various types of solid tumors and leukemias by discovering new and more active agents and combinations. New drugs may originate in synthetic laboratories at the Sloan-Kettering Institute or be received from pharmaceutical houses, university departments of chemistry, or from the Division of Cancer Treatment of the National Cancer Institute at various levels of the screening evaluation procedure. These synthetic and screening efforts as well as preclinical toxicology and pharmacology studies of many of the new drugs are done by various laboratories in SKI. Similarly, ideas for useful combinations may come from our own mouse tumor laboratories, from other investigators, or from our own experience with the activities and toxicities of different drugs. The use of cytokinetic, biochemical and immunologic markers both to help in the diagnosis and particularly the prognosis and selection of therapeutic regimens is greatly facilitated by the cooperation with various groups in SKI not supported by this grant. The strengths of this Program Project lie primarily in the fact that we have a very large accession of cancer patients at Memorial Hospital, most of whom are available for protocol studies, combined with the extensive facilities of the Sloan-Kettering Institute available for the development of new agents and studies on their mechanism of action. Thus, the discoveries made in the laboratories can be more rapidly utilized in the clinic, and the expertise of the basic scientists be made available to solve the questions posed by the neoplastic diseases in the patient.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Memorial Hospital for Cancer & Allied Di
New York
United States
Zip Code
Tedeschi, Philip M; Vazquez, Alexei; Kerrigan, John E et al. (2015) Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Mol Cancer Res 13:1361-6
Bell, Melanie L; Kenward, Michael G; Fairclough, Diane L et al. (2013) Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 346:e8668
Zhou, Ping; Hoffman, James; Landau, Heather et al. (2012) Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 12:49-58
Rizvi, Naiyer A; Rusch, Valerie; Pao, William et al. (2011) Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 17:3500-6
Zhao, Binsheng; Oxnard, Geoffrey R; Moskowitz, Chaya S et al. (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-53
Klimek, Virginia M; Fircanis, Sophia; Maslak, Peter et al. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14:826-32
Riely, Gregory J; Kris, Mark G; Zhao, Binsheng et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5
Zhao, Binsheng; Schwartz, Lawrence H; Moskowitz, Chaya S et al. (2006) Lung cancer: computerized quantification of tumor response--initial results. Radiology 241:892-8
Maslak, P; Chanel, S; Camacho, L H et al. (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20:212-7
Yankeelov, Thomas E; Rooney, William D; Huang, Wei et al. (2005) Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 18:173-85

Showing the most recent 10 out of 39 publications